Pfizer, Arvinas’ breast cancer drug combo keeps momentum after Phase 1b update
Pfizer and Arvinas’ targeted protein degrader plus Ibrance has shown promising efficacy in breast cancer patients in updated data from an early-stage trial, raising anticipation …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.